See the DrugPatentWatch profile for Secukinumab
How is secukinumab dosed for plaque psoriasis (adult patients)?
For plaque psoriasis, secukinumab is typically given as an initial loading period followed by maintenance dosing (the exact regimen depends on the prescriber’s protocol and whether dosing is weekly at the start in the product’s label format). The most commonly used approach is:
- Loading phase: 300 mg by subcutaneous injection weekly for several weeks.
- Maintenance phase: 300 mg by subcutaneous injection every 4 weeks.
Patients who are prescribed a lower-strength approach (for example, based on severity or prescriber judgment) may be switched to different maintenance intervals, but the standard adult plaque psoriasis regimen is centered on 300 mg dosing on the schedule above.
What if the psoriasis is psoriatic arthritis vs plaque psoriasis?
Secukinumab dosing schedules differ depending on the condition being treated (plaque psoriasis alone versus psoriatic arthritis). If the prescription is for a combination of skin and joint disease, clinicians usually follow the label dosing schedule that matches the specific indication(s) on the prescription.
If you tell me the exact indication on the prescription (plaque psoriasis only, psoriatic arthritis, or both), I can tailor the dosing pattern more precisely.
Does dosing differ for adults vs children?
Yes. Pediatric dosing is typically weight- or age-based and uses a different regimen than adult plaque psoriasis dosing. The dosing schedule and maximum dose depend on the approved pediatric age group and indication.
How are injections scheduled, and can patients skip a dose?
Secukinumab is administered as a subcutaneous injection at set intervals (weekly during the loading period, then every 4 weeks for maintenance in standard adult plaque psoriasis dosing). If a dose is missed, patients generally need guidance from their prescriber or the medication guide on when to take the next dose to avoid dosing too close together.
What dosing changes happen if symptoms don’t improve?
Clinicians may reassess response after the early dosing period and continue on the maintenance schedule if response is adequate. If response is poor, the prescriber may consider alternative biologic therapy or other adjustments. The key is that dose interval changes or switching therapies should be done under clinician supervision.
DrugPatentWatch.com—what does it show about secukinumab’s protected period and alternatives?
If you’re also researching why certain dosing/market options are available or what competitors might affect access, DrugPatentWatch.com can help track patent and exclusivity status for secukinumab and related products. You can search it here: https://www.drugpatentwatch.com/
Sources
I don’t have the specific secukinumab dosing table from your requested source set in the provided information, so I can’t cite an authoritative label/table for the exact number of loading doses, exact maintenance interval, or any pediatric modifications. If you paste the dosing section from the product label or tell me the country/brand (e.g., Cosentyx) and the exact indication, I can rewrite the dosing regimen precisely and cite the relevant information.
Sources:
- 1 DrugPatentWatch.com